08:56 AM EST, 11/07/2024 (MT Newswires) -- Immunovant ( IMVT ) reported a fiscal Q2 net loss Thursday of $0.74 per diluted share, widening from a loss of $0.45 a year earlier.

Analysts polled by Capital IQ expected a loss of $0.60.

The clinical-stage immunology company didn't report any revenue for the quarter ended Sept. 30, as expected by analysts surveyed by Capital IQ.

The company's shares were up more than 1% in recent premarket activity.

Price: 29.10, Change: -0.29, Percent Change: -0.99